Get started
Author

David H. Gallinson

Observed names: D. Gallinson, David Gallinson
OpenAlex ID: A5113225676
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 · Ghassan K Abou-Alfa, Vaibhav Sahai, et al. · The Lancet Oncology · 1,615
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202
2024 · A. Vogel, V. Sahai, et al. · ESMO Open · 105
PDF
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
2025 · Michael Wang, Michael Wang, et al. · Journal of Clinical Oncology · 67
FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
2019 · A. Vogel, V. Sahai, et al. · Annals of Oncology · 59
Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer
2013 · Johanna C. Bendell, Thomas J. Ervin, et al. · Clinical Colorectal Cancer · 34
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis
2024 · Michael Wang, Tadeusz Robak, et al. · Blood Advances · 28
Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.
2021 · Ghassan K. Abou-Alfa, Vaibhav Sahai, et al. · Journal of Clinical Oncology · 23
O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202
2022 · A. Vogel, V. Sahai, et al. · Annals of Oncology · 20
A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC).
2025 · Joel R. Hecht, Alexander I. Spira, et al. · Journal of Clinical Oncology · 12
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial
2024 · Tycel Phillips, Michael Wang, et al. · Haematologica · 8
PDF
Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)
2021 · Michael Wang, Tadeusz Robak, et al. · Blood · 8
Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis
2022 · Michael Wang, Tadeusz Robak, et al. · Blood · 6
Safety and efficacy of ABR in pts with TN or R/R MCL: Ph Ib trial.
2023 · Tycel Jovelle Phillips, Michael Wang, et al. · Journal of Clinical Oncology · 5
Pemigatinib for Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
2019 · Ghassan Abou-Alfa, Vaibhav Sahai, et al. · SSRN Electronic Journal · 2
P18 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202
2022 · Arndt Vogel, Vaibhav Sahai, et al. · Abstracts · 1
SO-4 Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response
2021 · G. Abou-Alfa, V. Sahai, et al. · Annals of Oncology · 1
PDF
A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating onartuzumab (MetMAb) in combination with mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
2012 · Johanna C. Bendell, Thomas J. Ervin, et al. · Journal of Clinical Oncology · 1
Clinical practice issues in oncology impacted by healthcare reform.
2012 · Alan J Lippman, David Gallinson, et al. · PubMed · 1
Demographic characteristics and inpatient outcomes of early-onset pancreatic cancer in the United States.
2026 · Kristy Rose Bono, Safia Ansari, et al. · Journal of Clinical Oncology
438 | Orelabrutinib for the Treatment of Relapsed/refractory Mantle Cell Lymphoma: Efficacy and Safety Results From a Global Phase 1/2 Study
2025 · Y. Wang, J. D'Olimpio, et al. · Hematological Oncology
PDF
P1094: Safety and Efficacy of Acalabrutinib, Bendamustine, and Rituximab in Patients With Treatment-naive or Relapsed/refractory Mantle Cell Lymphoma: Phase Ib Trial
2023 · Tycel Phillips, Michael Wang, et al. · HemaSphere
Safety and Efficacy of Acalabrutinib, Bendamustine, and Rituximab in Patients with Treatment‐Naive or Relapsed/Refractory Mantle Cell Lymphoma: Phase Ib Trial
2023 · T. Phillips, M. Wang, et al. · Hematological Oncology
PDF
Works count: 22
Citation count: 1,994
H-index: 9
I10-index: 9
Year
Topic
Type